Galbán Craig J, Lemasson Benjamin, Hoff Benjamin A, Johnson Timothy D, Sundgren Pia C, Tsien Christina, Chenevert Thomas L, Ross Brian D
Department of Radiology, University of Michigan, Ann Arbor, MI.
Department of Biostatistics, University of Michigan, Ann Arbor, MI.
Tomography. 2015 Sep;1(1):44-52. doi: 10.18383/j.tom.2015.00124.
Quantitative magnetic resonance imaging (MRI)-based biomarkers, which capture physiological and functional tumor processes, were evaluated as imaging surrogates of early tumor response following chemoradiotherapy in glioma patients. A multiparametric extension of a voxel-based analysis, referred as the parametric response map (PRM), was applied to quantitative MRI maps to test the predictive potential of this metric for detecting response. Fifty-six subjects with newly diagnosed high-grade gliomas treated with radiation and concurrent temozolomide were enrolled in a single-site prospective institutional review board-approved MRI study. Apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired before therapy and 3 weeks after therapy was initiated. Multiparametric PRM (mPRM) was applied to both physiological MRI maps and evaluated as an imaging biomarker of patient survival. For comparison, single-biomarker PRMs were also evaluated in this study. The simultaneous analysis of ADC and rCBV by the mPRM approach was found to improve the predictive potential for patient survival over single PRM measures. With an array of quantitative imaging parameters being evaluated as biomarkers of therapeutic response, mPRM shows promise as a new methodology for consolidating physiologically distinct imaging parameters into a single interpretable and quantitative metric.
基于定量磁共振成像（MRI）的生物标志物可捕捉肿瘤的生理和功能过程，被评估为胶质瘤患者放化疗后早期肿瘤反应的影像替代指标。一种基于体素分析的多参数扩展方法，即参数反应图（PRM），被应用于定量MRI图谱，以测试该指标检测反应的预测潜力。56例新诊断的高级别胶质瘤患者接受放疗并同步替莫唑胺治疗，纳入一项单中心前瞻性机构审查委员会批准的MRI研究。在治疗前及开始治疗3周后采集表观扩散系数（ADC）图和相对脑血容量（rCBV）图。多参数PRM（mPRM）应用于生理MRI图谱，并被评估为患者生存的影像生物标志物。为作比较，本研究还评估了单生物标志物PRM。结果发现，通过mPRM方法同时分析ADC和rCBV，比单PRM测量更能提高患者生存的预测潜力。随着一系列定量成像参数被评估为治疗反应的生物标志物，mPRM有望成为一种将生理上不同的成像参数整合为单一可解释定量指标的新方法。
